Molecular Prognostication in CLL from FISH to Next Generation Sequencing: Implications for Clinical Management
This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Summarize the prognostic significance of new genomic alterations and their potential clinical implications in the management of patients with CLL
Jennifer R. Brown, MD, PhD
Dana-Farber/Brigham and Women's Cancer Center
- 0.50 Participation
- 0.44 Nurse
- 0.50 Pharmacist
- 0.50 Physician